This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody & ADC Summit At ChinaBio
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026

Dr. Yongliang Fang, PhD
COO at Doer Biologics
Speaker

Profile

Dr. Yongliang Fang obtained his Ph.D. from Dartmouth College. His main research interests include protein engineering, immunogenicity analysis, protein deimmunization, drug discovery, and clinical translation. As a co-founder and Chief Operating Officer of Occulo Holdings, LLC, he led Occulo's Series A financing, pipeline development, in-licensing of key assets, and out-licensing of preclinical programs. Currently, he serves as the Chief Operating Officer of Zhejiang Doer Biologics Co., Ltd., where he is primarily responsible for regulatory affairs, clinical translation and operations, and business development for Doer Bio's innovative biotherapeutics.

Agenda Sessions

  • The MultipleBody and AccuBody Enabled Development of Multi-Specific Biotherapeutics for Unmet Medical Needs

    15:45